newsfilter
← Earnings
Earnings Releases·

Indaptus Therapeutics — Third Quarter 2026 Earnings Summary

  • Net loss narrowed to approximately $1.0 million in Q3 2026 from $3.0 million in the prior year period, with full-year-to-date losses declining to $5.4 million from $12.7 million, driven by 82% and 24% reductions in R&D and G&A expenses respectively.
  • The Company secured a $24.0 million private placement (closing October 2026), resulting in $20.5 million in proceeds recorded by September 30, 2026, which increased total assets to $31.2 million and stockholders' equity to $10.3 million.
  • Management is pivoting strategy to explore early-stage research and preclinical evaluation of a neurotechnology device for sleep-related conditions while evaluating the existing Decoy platform for potential licensing or partnership opportunities.
  • Liquidity remains sufficient to fund anticipated operating expenses and planned R&D activities, though the Company faces risks related to its limited operating history, discontinued Decoy20 clinical activities, and potential future capital dilution.
Company
INDAPTUS THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology